RSS   Newsletter   Contact   Advertise with us

Five Prime Therapeutics selects Aron Knickerbocker as CEO

Share on Twitter Share on LinkedIn
Staff Writer | San Francisco, Ca., USA | October 24, 2017
Five Prime TherapeuticsOctober 24, 2017, San Francisco, Ca., USA - Five Prime Therapeutics, a clinical-stage biotechnology company, announced that it has selected Aron Knickerbocker as president and CEO effective January 1, 2018.
Mr. Knickerbocker is currently Five Prime’s Chief Operating Officer, and will maintain that position until the end of 2017.

Mr. Knickerbocker has been a member of the Board of Directors since 2013 and will continue to serve his term once CEO.

Mr. Knickerbocker joined Five Prime in 2009 to lead the company’s business development efforts, eventually serving as Executive Vice President and Chief Business Officer and later COO.

Prior to Five Prime, he served at Genentech for eight years in positions of increasing responsibility, including leading the oncology business development team as Senior Director, Business Development.

Previously, Mr. Knickerbocker served as Director of Commercial Development at ALZA Corporation (which was acquired by Johnson & Johnson), and in oncology sales, marketing and corporate development roles at Amgen, and as a research scientist at BMS.

He received an A.B. in biology from Washington University in St. Louis and an M.B.A. from the University of Michigan.